Median age at diagnosis, years (range) | 53 (16–83) |
Male | 47 (53) |
Race | |
Caucasian | 70 (79) |
Othert | 4 (4) |
Unknown | 15 (17) |
Eye | |
Left | 38 (43) |
Right | 37 (42) |
Unknown | 14 (16) |
Stage at diagnosis | |
Limited | 83 (93) |
Metastatic | 5 (6) |
Unknown | 1 (1) |
Molecular risk | |
High | 28 (31) |
Low | 3 (3) |
Unknown | 58 (65) |
Time to metastasis, mo (range) | 37.8 (3.7–212.7) |
Median no of prior therapies, no (range) | 0 (0–4) |
Received prior therapy | |
Any prior therapy | 40 (45) |
Liver directed therapy | 26 (29) |
Systemic therapy | 25 (28) |
Radiation | 13 (15) |
Immunotherapy | 20 (22) |
Targeted therapy | 12 (13) |
Chemotherapy | 2 (2) |
Performance status at treatment start | |
0 | 50 (56) |
1 | 21 (24) |
2 | 4 (4) |
Unknown | 14 (16) |
LDH at treatment start | |
Normal | 23 (26) |
High | 16 (18) |
Unknown | 50 (56) |